Standard Biotools Inc. revenue by segment LAB

Annual Quarterly

Standard Biotools Inc. splits its revenue into 6 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Consumables at $8.3 million, 43% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	84	19	20	21	24	20	22	20	25
Assay Services	—	—	—	—	—	—	—	—	16 share 63.4%
Consumables	38 -1.1% share 44.6%	8 -4.3% share 43.0%	9 -10.3% share 46.7%	11 +35.0% share 51.9%	9 -39.0% share 37.6%	9 share 44.5%	10 share 48.1%	8 share 40.2%	15 share 59.2%
Instruments	24 -2.3% share 28.5%	6 +17.7% share 30.9%	5 -1.6% share 25.5%	4 -32.7% share 21.1%	8 -1.1% share 35.5%	5 share 26.1%	5 share 24.0%	7 share 32.9%	9 share 34.5%
Instrument Support Services	—	—	—	—	—	—	—	—	6 share 23.9%
Services And Other Revenue	23 -3.8% share 26.9%	5 -12.1% share 26.1%	6 -8.2% share 27.8%	6 +4.6% share 26.9%	6 +0.9% share 26.9%	6 share 29.4%	6 share 28.0%	5 share 26.9%	6 share 25.6%
Collaboration And Other Revenue	—	—	—	—	—	—	—	—	2 share 7.6%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: LAB (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Boston, MA
SEC filer status: Accelerated filer
SEC CIK: 1162194
Former names: FLUIDIGM CORP (until Apr 1, 2022)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.